0001127602-20-019791.txt : 20200616
0001127602-20-019791.hdr.sgml : 20200616
20200616181902
ACCESSION NUMBER: 0001127602-20-019791
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200612
FILED AS OF DATE: 20200616
DATE AS OF CHANGE: 20200616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Basil Michelle L
CENTRAL INDEX KEY: 0001699629
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14041
FILM NUMBER: 20967559
MAIL ADDRESS:
STREET 1: HAEMONETICS CORPORATION
STREET 2: 400 WOOD ROAD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HAEMONETICS CORP
CENTRAL INDEX KEY: 0000313143
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042882273
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0328
BUSINESS ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 7818487100
MAIL ADDRESS:
STREET 1: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-06-12
0000313143
HAEMONETICS CORP
HAE
0001699629
Basil Michelle L
125 SUMMER STREET
BOSTON
MA
02110
1
EVP and General Counsel
Common Stock
2020-06-12
4
A
0
24014
0
A
40390
D
Common Stock
2020-06-12
4
S
0
203
89.29
D
40187
D
Common Stock
2020-06-15
4
S
0
10578
87.71
D
29609
D
Common Stock
2020-06-16
4
S
0
5175
90.32
D
24434
D
Common Stock
2020-06-16
4
S
0
6961
91.34
D
17473
D
Common Stock
2020-06-16
4
S
0
1300
92.14
D
16173
D
Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020.
This number includes unvested restricted stock units ("RSUs") previously reported.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Transaction pursuant to an existing 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.93 to $90.93, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) through (8) to this Form 4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.95 to $91.93, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.24, inclusive.
/s/ Thomas V. Powers, attorney-in-fact for Ms. Basil
2020-06-16